Posted by Michael Wonder on 21 Dec 2024
Knight Therapeutics announces filing of new drug submission for Qelbree (viloxazine) in Canada
16 December 2024 - Knight Therapeutics announced today that Knight's new drug submission for Qelbree (viloxazine extended-release capsules) has been accepted for review by Health Canada.
Qelbree is a novel non-stimulant medication for the treatment of attention-deficit hyperactivity disorder.
